The potential of using circulating PTX3 as a biomarker for BC has been investigated previously by Goodison et al. In their study, no difference was found when comparing urinary levels of PTX3 in patients with newly diagnosed BC and BC-free patients [17]. This evidence concerns the gene PTX3 and breast cancer.